# Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

> **NCT02272998** · PHASE2 · COMPLETED · sponsor: **Sameek Roychowdhury** · enrollment: 22 (actual)

## Conditions studied

- Malignant Neoplasm

## Interventions

- **DRUG:** ponatinib hydrochloride
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT02272998
- **Lead sponsor:** Sameek Roychowdhury
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-24
- **Primary completion:** 2022-11-17
- **Final completion:** 2022-11-17
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02272998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02272998, "Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02272998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*